Physician profile
Mary Olson
NPI 1497488779
$2,535.69
in general payments reported to CMS, 2019-2025
14 companies · $851 in 2025
The $851 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $107 · 2023: $537 · 2024: $1,040 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $664.05 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $388.89 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $377.73 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $343.87 | 2022-2025 | Rexulti |
| Axsome Therapeutics, INC. | $316.20 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $113.74 | 2023-2024 | Spravato |
| Vanda Pharmaceuticals INC. | $81.76 | 2024-2025 | Fanapt |
| Alkermes, INC. | $65.98 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $53.09 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $38.13 | 2024-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $31.41 | 2023-2025 | Quviviq, Quviviq |
| Teva Pharmaceuticals USA, INC. | $28.89 | 2023 | Austedo Xr |
| Collegium Pharmaceutical, INC. | $17.87 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $14.08 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.